Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas.

about

Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas.

Item

http://www.wikidata.org/entity/Q51565283

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas.

@en

Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas.

@nl

type

Item

label

Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas.

@en

Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas.

@nl

prefLabel

Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas.

@en

Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas.

@nl

P1476

Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas.

@en

P2093

P L Ortiz-Romero

http://www.w3.org/2001/XMLSchema#string

P2860

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

WHO-EORTC classification for cutaneous lymphomas.

Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.

KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.

IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma.

P304

246-247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJD.14783

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

175

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27535600

http://www.w3.org/2001/XMLSchema#string